CD274 and non-small cell lung carcinoma: Not surprisingly, regardless of PD-L1 expression, PFS was significantly prolonged and maintained with sugemalimab plus chemotherapy compared with placebo plus chemotherapy, suggesting an emerging strategy for the first-line treatment of squamous and non-squamous metastatic NSCLC is coming soon.